Thelansis

  Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) that is defined by the presence of a balanced reciprocal translocation between chromosomes 15 and 17, which results in the fusion of promyelocytic leukemia (PML) gene and retinoic acid receptor-α (RARα) gene. Historically, APL has been known to have a severe bleeding tendency and a poor prognosis. APL accounts for approximately 10 to 15% of all adult AML cases diagnosed in the United States annually. The clinical presentation of APL typically includes symptoms such as pallor secondary to anemia, bleeding, fatigue, mild fever, swollen gums, frequent minor infections, loss of appetite, weight loss, discomfort in bones or joints, enlarged spleen, and enlarged liver. The disease is most commonly diagnosed in patients between 20 and 50. The primary treatment for APL is all-trans retinoic acid (ATRA), also known as tretinoin. This targeted therapy aims to induce the differentiation of promyelocytes, which...

 Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) that is defined by the presence of a balanced reciprocal translocation between chromosomes 15 and 17, which results in the fusion of promyelocytic leukemia (PML) gene and retinoic acid receptor-α (RARα) gene. Historically, APL has been known to have a severe bleeding tendency and a poor prognosis. APL accounts for approximately 10 to 15% of all adult AML cases diagnosed in the United States annually. The clinical presentation of APL typically includes symptoms such as pallor secondary to anemia, bleeding, fatigue, mild fever, swollen gums, frequent minor infections, loss of appetite, weight loss, discomfort in bones or joints, enlarged spleen, and enlarged liver. The disease is most commonly diagnosed in patients between 20 and 50. The primary treatment for APL is all-trans retinoic acid (ATRA), also known as tretinoin. This targeted therapy aims to induce the differentiation of promyelocytes, which th...